Belite Bio BLTE
$127.38 −$23.64 (-15.65%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $127.38 0.00%
Open$129.00
Prev close$151.02
Day range$120.00 – $135.07
Volume1.04M
Market cap$5.17B
P/E (TTM)–
Dividend yield–
BLTE Stock News
Headlines matching Belite Bio or the BLTE ticker, most recent first.
- Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $234 Positive
- Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)
- H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245
- H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $245 Positive
- Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $220
- CCORF Initiates Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $303
- H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $214
- BofA Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $200
- Belite Bio(BLTE.US) Officer Sells US$12.8 Million in Common Stock
- Belite Bio(BLTE.US) Officer Sells US$19.08 Million in Common Stock
- Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
- Morgan Stanley Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $206 Positive
- Maxim Group Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $200
- Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)
- Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE)
No comments yet — be the first to weigh in on BLTE.
Sign in to join the discussion.